Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 20/20 | 1.00 |
| ▸ | IRAK2 | O43187 | 1/20 | 1.00 |
| ▸ | CLK1 | P49759 | 1/20 | 1.00 |
| ▸ | CLK2 | P49760 | 1/20 | 1.00 |
| ▸ | IRAK1 | P51617 | 1/20 | 1.00 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 1.00 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 1.00 |
| ▸ | IRAK3 | Q9Y616 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30264224 | 1.00 | IRAK4 (1.00) | IRAK4IRAK2CLK1CLK2IRAK1 | |
| SCHEMBL21106082 | 1.00 | IRAK4 (1.00) | IRAK4IRAK2CLK1CLK2IRAK1 | |
| SCHEMBL21105720 | 1.00 | IRAK4 (1.00) | IRAK4IRAK2CLK1CLK2IRAK1 | |
| SCHEMBL23860570 | 1.00 | IRAK4 (1.00) | IRAK4IRAK2CLK1CLK2IRAK1 | |
| SCHEMBL21070419 | 0.93 | IRAK4 (0.86) | IRAK4IRAK2CLK1CLK2IRAK1 | |
| SCHEMBL31664231 | 0.93 | IRAK4 (0.86) | IRAK4IRAK2CLK1CLK2IRAK1 | |
| SCHEMBL21107419 | 0.93 | IRAK4 (0.86) | IRAK4IRAK2CLK1CLK2IRAK1 | |
| SCHEMBL23945382 | 0.92 | IRAK4 (0.84) | IRAK4IRAK2CLK1CLK2IRAK1 | |
| SCHEMBL23945438 | 0.92 | IRAK4 (0.84) | IRAK4IRAK2CLK1CLK2IRAK1 | |
| SCHEMBL22906395 | 0.92 | IRAK4 (0.84) | IRAK4IRAK2CLK1CLK2IRAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12295955-B2 | TTP phosphorylation for the identification of personalized medicines | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2025-05-13 | — | — | US | disclosed |
| US-20240390406-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTIAGING DRUGS | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2024-11-28 | — | — | US | disclosed |
| EP-4467978-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTI-AGING DRUGS | King Faisal Specialist Hospital & Research Centre (SA) | 2024-11-27 | — | — | EP | disclosed |
| US-20240116893-A1 | Compounds for Disease Treatment | DUKE UNIVERSITY | 2024-04-11 | — | — | US | disclosed |
| US-20230310437-A1 | TTP PHOSPHORYLATION FOR THE IDENTIFICATION OF PERSONALIZED MEDICINES | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2023-10-05 | — | — | US | disclosed |
| WO-2023192586-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-11648251-B2 | TTP phosphorylation as a biomarker in targeted therapy | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2023-05-16 | — | — | US | disclosed |
| WO-2022164822-A1 | COMPOUNDS FOR DISEASE TREATMENT | DUKE UNIVERSITY (US) | 2022-08-04 | — | — | WO | disclosed |
| WO-2021159993-A1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR ASSOCIATED KINASE (IRAK) /FMS-LIKE RECEPTOR TYROSINE KINASE (FLT3), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | PHARMABLOCK SCIENCES (NANJING) , INC. (CN) | 2021-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116893-A1 | Compounds for Disease Treatment | TRAF6, CNKSR1, TBK1 | IRAK4 14/4885IRAK2 4/4885CLK1 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.